| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
body weight
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Various interventions vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
|
colony observation
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Life span study. Various interventions vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
|
DXA
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Body composition. Body mass, fat mass, lean mass, water content. Intervention vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
|
glucose tolerance
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Postprandial glucose. Invervention vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
|
grip strength
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Interventions vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
|
histopathology
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Pathology. Percent lesions in liver degeneration, lung tumor, renal organs. Intervention vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
|
rotarod
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Interventions vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
|
uterus weight
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Uterus weight, ovariectomy study with and without an intervention. | UM-HET3 population | both | various | 2004-2024 |
|
|
study archive
with captopril |
Effect of captopril on hyperglycemia in a strain with induced type 1 diabetes. | one strain: C57BL/6J | m | 2009 |